NextGen Bioscience, Inc. is a drug development biotechnology company focused on the identification, evaluation and acquisition of drug candidates for treatment and prevention of oncological and infectious diseases in human beings. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical companies.
NextGen’s business model is to acquire promising new patented technologies in the fields of cancer and infectious disease, to add significant value to these by advancing them through toxicological assessment or Phase I clinical trials and then outlicensing the technology to a larger partner who has the necessary infrastructure to take the products to market. All acquisition candidates are underpinned by patent applications or granted patents which confer protection in the major jurisdictions worldwide. Revenues generated from licensing activities will be reinvested in research and development by NextGen to benefit patients, partners and the Company’s investors.
NextGen’s target market for effective cancer therapeutics is the world’s largest disease market, exploding at a 20% growth rate each year, reaching a global market volume of approximately $30 Billion, and projected to rise to $60.6 Billion by 2011.
All of NextGen’s proprietary product candidates target indications which are significant unmet needs, with blockbuster potential. In the event that the drug targets are successful, and based upon deals achieved by other successful drug targets in the industry, NextGen can expect up to $100 million in milestone payments per licensed product during clinical trials, and up to $400 million per annum in the years (up to 20 years) following commercialization. With market growth, NextGen’s licensing fees could grow to $700 million per annum per product. This represents a significant catalyst for company growth which will in turn greatly benefit stakeholders.
New Proprietary Products
NextGen is rapidly building its portfolio of proprietary biotechnology. The Company’s patented drug and product portfolio includes a prostate cancer target and a breast cancer target as well as a promising acquisition pipeline. These first two anti-tumor drug candidates, Prostaganin (prostate cancer) and Tetanolic (breast cancer) — both have incredible market potential. With the potential to treat cancer in a way that is effective and safe for the patient, they may ultimately eliminate the need for surgery and chemotherapy and possess no side effects. An exciting acquisition pipeline, including in oncology therapeutics, cancer vaccines and anti-bacterial drugs, ensures that the Company is constantly positioned as a leader in the forefront of developments in treating cancer and infectious disease.
New product candidates being evaluated for potential acquisition include a number of biological products which enable the destruction of a broad range of solid tumors, including colorectal and ovarian cancers. The Company is also evaluating the potential of a protein drug which has shown potency in preventing bacterial infection. This product has a novel mechanism of action and could potentially revolutionarise the prevention of hospital acquired infections, such as MRSA or C.difficile. These, and other future acquisitions, will ensure that NextGen’s pipeline of products are maintained at the forefront of scientific and medical developments, again, bringing maximum benefit to stakeholders.
Based in London, NextGen is able to keep operating costs to a minimum by outsourcing all product development work to established specialist service providers and Universities to add significant value, but at low cost. NextGen’s World Class Management team and Scientific Advisory Board will guide and direct development of the products to add maximum value.
Key parameters differentiating NextGen from other biotechnology companies:
1. NextGen’s Corporate focus is devoted to identification, evaluation and acquisition of drug targets and subsequent value addition to maximize benefits to stakeholders.
2. The Company’s World-class Management Team and Scientific Advisory Board directs product development, each with specialist experience in this field.
3. Potential value is built in the portfolio of pending patent applications for treatment of difficult to treat cancers – NextGen’s proprietary Intellectual Property.
4. The Pipeline of acquisition candidates being evaluated is derived from global collaborations with other biotechnology companies and Universities.
5. Strategy of acquiring candidates aims to target indications with significant unmet needs and blockbuster market potential.
6. Due to outsourcing strategy, NextGen maintains a Highly Flexible organization and low fixed overheads.
7. The Company obtains Leverage of resources through collaboration with well established service providers and academic laboratories.
8.The Company’s Opportunistic approach is characterized by swift decision making and ability to redirect research and business efforts quickly and at low cost, to maximize partnering activities.
The main target indication area is cancer treatment and in particular:
1. Prostate cancer
2. Breast cancer
3. Colorectal cancer
NextGen’s treatment niche is based on recent discoveries that indicate that most tumors are derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell). NextGen has chosen to concentrate on identification of certain cell-specific characteristics, making it possible to identify precursor cells of tumors, and then conduct a more extensive ‘fingerprinting’ profile that will enable the development of cell-specific anti-cancer treatments. This will result in a ‘tailor made’ cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.
Global Collaboration
On February 21 NextGen signed a Letter of Intent to come to a collaboration agreement with SymbioTec GmbH (”SymbioTec”), a German company that has developed and patented ONCOHIST, an effective and commercially attractive cancer-fighting compound. Cell culture and in vivo studies demonstrated that ONCOHIST is active against a variety of solid tumors like breast, ovarian and lung cancer as well as blood cancer types including drug-resistant cancers. Due to its unique mode of action and promising clinical outcomes, SymbioTec expects that ONCOHIST will act synergistically with several classes of approved cancer drugs in combination therapies or has the potential to replace current chemotherapies.
On February 19 NextGen announced that it was in collaboration negotiations with Warburg Glycomed, a biopharmaceutical company that has developed a new class of drugs which has shown potent anti-cancer properties in animal models. Warburg Glycomed has a patent-protected compound that is able to reprogram cancer cells by modulating their aerobic glucose metabolism, which affects their ability to grow. Warburg Glycomed has expressed keen interest in collaborating with NextGen in a signed Letter of Intent.
Fast Track
NextGen’s business model of global outsourcing, international collaboration, the benefit of advice from leading experts in the field and use of regulatory fast-tracking ensures accelerated drug development – and early exit to larger biotech or pharma companies which have the necessary infrastructure to develop the products further. By bridging the gap between academic research groups and smaller biotech companies and the clinic, the fast track route is cost efficient and provides a longer exclusivity period in the market, thereby maximizing earnings potential and minimizing investor risk. Through a flexible and scalable organization due to out-sourcing NextGen positions itself to make superior treatments available faster for patient and society.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC has been compensated 37,000 shares of free trading stock from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.